Table 2: Level of Risk of Oncologic Treatments in ECG QT Segment Prolongation.
| Class or Drugs | Specific Agents Responsible for CTRCD | Risk |
|---|---|---|
| Anthracyclines | Aclarubicin Doxorubicin Epirubicin Idarubicin Mitoxantrone |
Very low |
| Anti-metabolites | 5-Fluorouracil Capecitabine Gemcitabine Pentostatin |
High |
| Anti-microtubule agents | Docetaxel Paclitaxel Vinblastine Vincristine |
Low |
| Cyclin-dependent kinase inhibitor | Ribociclib | High |
| HER2 inhibitors | Lapatinib Pertuzumab Trastuzumab |
Low |
| Immune checkpoint inhibitors | Ipilimumab Nivolumab Pembrolizumab |
Low |
| Other anti-neoplastic agents | Arsenic trioxide | High |
| Platinum-based anti-neoplastic class | Oxaliplatin | High |
| Proteasome inhibitors | Bortezomib Carfilzomib |
Low |
| Selective oestrogen receptor modulator | Toremifene | |
| Tyrosine kinase inhibitor | Nilotinib Pazopanib Sorafenib Sunitinib Vandetanib Vemurafenib |
High |
CTRCD = cancer therapy-related cardiac dysfunction; HER2 = human epidermal growth factor receptor 2.